Immunome’s Acquisition of AL102: A Boost for Desmoid Tumor Treatment

by Ron Finklestien

Published On: February 6, 2024 8:17 am

• Immunome (NASDAQ:IMNM) Tuesday announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals (OTCQX:ADXS), a clinical-stage oncology company, to acquire AL102 and related drug candidate AL101 from Ayala.
• Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash and $30 million in Immunome common stock at the closing and will pay up to an additional $37.5 million in development and commercial milestone payments.
• AL102 is a potential once-daily oral treatment for desmoid tumors. Data from clinical trials have shown AL102 may be more effective in treating desmoid tumors than OGSIVEO (nirogacestat), which recently became the first treatment approved for desmoid tumors by the U.S. Food and Drug Administration in November 2023.
• The dose is being evaluated in the current Phase 3 trial.
• Source: Press Release

Insight into the Acquisition